full-length AR level. Triptolide decreased viability of 22Rv1 in a dosedependent manner. Pretreatment with triptolide at 10 nM sensitized 22Rv1 to STA-9090 (IC50: 66 nM as single agent, 4.5 nM in combination).
INTRODUCTION AND OBJECTIVES: Introduction:
We reported functional driver genes and network interaction of race specific and differentially expressed genes by use of bioinformatics and ingenuity pathway analysis among a large population of African American men (AAM) and European American men (EAM) (Powell, I et al 2013, Cancer Epid Bio Prev.) . When unraveling the network we identified multiple biological signaling pathways, parts of which reported elsewhere, but when put together, they activate directly or indirectly the androgen receptor and other pathways associated with invasiveness and metastasis. The drivers of these pathways are pro-inflammatory cytokines. We will present these signaling pathways from our interactive network.
METHODS: Method: In our initial microarray analysis from formalin fixed radical prostatectomy specimens, we examined 227 genes from 517 genes associated with PCa showing significantly greater expression in PCa from AAM and EAM, and a subset of these genes were identified by bioinformatics and the network from Ingenuity Pathway analysis to be functionally interrelated and driver genes.
RESULTS: Results: Pro-Inflammatory cytokines TNF (tumor necrosis factor) IL1B, IL6 and IL8 from our gene profile activated several intermediaries that interact and activate transcription factors in the nucleus, NFkB and TGFB included in our network . These factors bind to the promoter region of the androgen receptor and promote PCa cell proliferation (Zhang 2009 ,Cao 2015 . Inflammatory cytokines TNF and IL1B up-regulate MMP9 (Matrix metalloproteinase 9) in the microenvironment which down regulates cell adhesion molecule E-Cadherin and allows tumors cells to become invasive (Zhang 1998 , Canbay, 2015 Beta Catenin that is released into the cytoplasm after down regulation of E-Cadherin by MMP9 is translocated to the nucleus by IL8 (WNT pathway) (Tung-Yuan Lai, 2010) . TNF and IL1B up regulate CXCR4 which facilitates movement of prostate cancer cells within the prostate and from the prostate to bone on lipid rafts (Han, 2001) . These pro-inflammatory cytokines are more expressed among AAM. CONCLUSIONS: Conclusion: These pro-inflammatory cytokines, the same cytokines identified in several other cancers and associated with aggressiveness and disease progression, are associated with PCa aggressiveness, disease progression and castrate resistant prostate cancer. These interactive pathways may become targets for therapy.
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MP64-16 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY INCREASES BOTH TUMOR-INFILTRATING LYMPHOCYTES AND SUPPRESSIVE IMMUNE CELLS IN PROSTATE CANCER
Lin Lin*, Nathan Kane, Naoko Kobayashi, Siliva Diaz-Perez, Rajan Kulkarni, Nicholas Nichols, Robert Reiter, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Extremely hypofractionated stereotactic body radiotherapy (SBRT) is a technique for delivering radiotherapy (RT) to prostate cancer that is growing in use due to improved convenience as compared to conventional radiotherapy and equivalent efficacy results. It is hypothesized that SBRT may enhance or suppress tumor reactive immunity. The goal of this study is to assess both the anti-tumor and immunosuppressive effects induced by SBRT in prostate cancer patients and experimental models, and ultimately, to test if a combination of SBRT with targeted immune therapy can achieve a superior antitumor effect.
METHODS: Twelve patients are recruited in our Phase I feasibility trial (NCT02830165) of hypofractionated SBRT followed by radical prostatectomy in high-risk localized prostate cancer. Pre-SBRT biopsies, post-SBRT prostatectomies, and sequential blood samples are collected to assess local radiation-induced tumor immunity and the development of systemic immune response. Syngeneic murine allograft prostate cancer models are used to study the dynamic change of tumorinfiltrating lymphocyte (TIL), T regulatory cell (Treg), myeloid-derived suppressive cell (MDSC), and circulating T memory cell. These immune cell populations from human prostates and experimental models are evaluated using flow cytometry.
RESULTS: Results from the first patients treated suggest that SBRT increased the density of TILs within the resected prostate tumor two-weeks after treatment, and the majority of the post-SBRT TILs were CD8þ T cells. Co-clinical syngeneic murine prostate cancer models demonstrated a drastic increase in tumor-infiltrating MDSCs immediately after a single RT dose and then a gradual rise of TILs. Besides local effects, irradiation of primary tumors also increased the fractions of MDSCs and Tregs in non-irradiated synchronous tumors, suggesting that hypofractionated SBRT induced a systemic immune response. CONCLUSIONS: In prostate cancer patients, hypofractionated SBRT may enhance CD8 T cell infiltration weeks after treatment. In murine prostate cancer models, RT induces an early rise of tumorinfiltrating MDSCs, a gradual increase of TILs, and a systemic immune response in non-irradiated tumors. The expansion of immunosuppressive cell populations induced by SBRT allows us to further explore the effectiveness of SBRT in combination with targeted immune therapies in prostate cancer.
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